Analyst Summary:
Viridian Therapeutics reported their full-year financial results for 2022 and discussed the progress made in their Thyroid Eye Disease (TED) program with lead product candidate VRDN-001. Positive data was reported in the ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with TED, and the first patient was enrolled in the THRIVE Phase 3 trial in patients with active TED, with results expected in mid-2024. Initial results from the proof-of-concept study of VRDN-001 in patients with chronic TED are expected in the second quarter of 2023, and selection for the lead subcutaneous program in TED is planned for year-end 2023. Viridian CEO Scott Myers notes the company's intention to continue the development of their TED programs, expand their current pipeline beyond TED by showcasing advancements in their preclinical programs later this year, and establish their commercial capabilities. The company's preclinical programs have the potential to provide best-in-class medicines that address known limitations of current therapies. Investors can participate in the conference call held on March 8 and monitor further updates on their pipeline. Forward-looking statements should be reviewed with caution as they are subject to risks and uncertainties beyond the company's control.